Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis by unknown
RESEARCH ARTICLE Open Access
Impaired phagocytosis and reactive oxygen
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Abstract
Background: Anti-neutrophil cytoplasmic antibodies associated vasculitides (AAV) is a group of autoimmune
diseases, characterized by small vessel inflammation. Phagocytes such as neutrophils and monocytes are the
main effector cells found around the inflamed vessel wall. Therefore, we wanted to investigate aspects of
function and activation of these cells in patients with AAV.
Methods: Flow cytometry was used to evaluate: the expression of activation markers (CD11c, CD62L, CD177
and C5aR); the number of recently released neutrophils from bone marrow, defined as CD10-D16low cells in
peripheral blood; and the capacity of peripheral blood monocytes and polymorphonuclear leukocytes (PMN)
to produce reactive oxygen species and to phagocytose opsonized bacteria.
Results: AAV patients (n = 104) showed an increase of CD10-CD16low neutrophils and total PMN in peripheral
blood, suggesting a combination of increased bone marrow release and prolonged survival. An increased
percentage of AAV PMN expressed CD177 but no other signs of activation were seen. A decreased production of
reactive oxygen species was observed in AAV phagocytes, which was associated with disease activity. Moreover,
granulocytes from patients with microscopic polyangiitis showed lower oxidative burst capacity compared to
patients with granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis. In addition,
decreased phagocytosis capacity was seen in PMN and monocytes.
Conclusion: Our results indicate that phagocytes from AAV patients have impaired function, are easily mobilized
from bone marrow but are not particularly activated. The association between low reactive oxygen species
formation in PMN and disease severity is consistent with findings in other autoimmune diseases and might be
considered as a risk factor.
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Background
Anti-neutrophil cytoplasmic antibody associated vascu-
litides (AAV) is a group of autoimmune diseases compris-
ing eosinophilic granulomatosis with polyangiitis (EGPA),
granulomatosis with polyangiitis (GPA) and microscopic
polyangiitis (MPA). AAV are conditions defined by auto-
immune small vessel inflammation [1] and characterized
by autoantibodies, the anti-neutrophil cytoplasmic anti-
bodies (ANCA). The ANCA antigens proteinase 3 (PR3)
and myeloperoxidase (MPO) are mainly present in the
primary granules of neutrophils and in the peroxidase
positive lysosomes of monocytes.
Neutrophils are found in abundance in and around
inflamed vessel walls in patients with AAV, and ANCA
bound to the target antigens leads to activation of neu-
trophil effector functions and ultimately tissue damage
[2]. In vitro experiments show that ANCA-mediated ac-
tivation of primed neutrophils leads to degranulation and
production of reactive oxygen species (ROS), complement
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activation [3], and release of neutrophil extracellular traps
(NETs) [4]. Furthermore, the pathological role of ANCA
has been shown in animal models where ANCA cause
vasculitis-like symptoms [5, 6].
Monocytes have been less studied than neutrophils,
but are known to be prominent in AAV lesions [7].
There are reports showing that ANCA can activate
monocytes and early exudative macrophages but not
mature macrophages [8–10].
Monocytes and PMN, such as neutrophils, are produced
in the bone marrow and released into the circulation.
Inflammation causes increased mobilization of PMN from
the bone marrow that is thought to be reflected by an
increased percentage of CD10-CD16low neutrophils in
peripheral blood [11, 12]. Upon activation the expression
of various surface proteins changes, e.g., C5aR and CD62L
are downregulated [13, 14] whereas increased CD11c
expression is observed [15]. In addition to the changing
expression of their surface proteins, activated monocytes
and neutrophils are primed to release granules and
produce ROS by the nicotinamide adenine dinucleo-
tide phosphate-oxidase (NADPH) complex [16]. ROS are
major effector molecules in inflammatory processes and
tightly linked to NET formation. During the last decade,
an increasing amount of data have been produced to sup-
port a T cell regulating role for monocyte-produced and
neutrophil-produced ROS [17–20].
This study aimed to characterize monocytes and PMN
from patients with AAV, in regard to function, bone
marrow release and activation, in order to understand
the role of these phagocytes in AAV and autoimmunity.
Methods
Patients and controls
Patients with AAV were recruited to the study when
attending their scheduled visit at the Department of
Nephrology or Rheumatology, Skåne University Hos-
pital, Lund, Sweden. Classification of AAV was done
according to the consensus methodology described by
Watts et121 al. in 2007 [21]. Patients with AAV (n = 104)
included in the study comprised 73 patients with GPA,
median age 66 years (range 20–84 years), 23 patients with
MPA, median age 72 years (range 20–84 years), and 8
patients with EGPA, median age 71 years (range 56–78
years). Patients with EGPA in this study had normal
eosinophil counts at the time of sampling, with a
mean of 0.2 × 109/L, range 0.01–0.6 × 109/L (reference
range <0.7 × 109/L). Disease activity was assessed using
the Birmingham Vasculitis Activity Score version 3
(BVAS 3) [22]. Demographic and clinical characteris-
tics are shown in Table 1. ANCA specificity was deter-
mined with ELISA at an accredited clinical laboratory
(Wieslab AB, Malmö, Sweden).
Table 1 Patients characteristics and demographics
All patients (n = 104) Remission BVAS3 = 0 (n = 82) Disease activity BVAS3 > 1 (n = 22)
Age, years, median (range) 68 (20–86) 68 (25–84) 66 (20–86)
Disease duration, years, median (range) 7 (0–50) 7 (0–50) 1 (0–31)
GPA, % (n) 70 % (n = 73) 68 % (n = 56) 78 % (n = 18)
MPA, % (n) 22 % (n = 23) 24 % (n = 19) 17 % (n = 4)
EGPA, % (n) 8 % (n = 8) 8 % (n = 7) 4 % (n = 1)
MPO-ANCA, % (n) 30 % (n = 32) 33 % (n = 26) 26 % (n = 6)
PR3-ANCA, % (n) 59 % (n = 61) 56 % (n = 46) 70 % (n = 16)
BVAS3, median (range) 0 (0–16) 0 4 (1–16)
Leukocytes, 109/L, median (range)a 6.4 (3.0–13.7) 6 (3.2–13.7) 7.9 (3.0–12)
P-creatinine, μmol/L, median (range) 98 (54–646) 96 (59–635) 143 (54–646)
P-CRP, mg/L, median (range) 2.6 (<0.6–92) 2.6 (<0.6–27) 5.7 (<0.6–92)
Treatmentb
Prednisone, % (median dose of treated patients) 60 % (6.25 mg) 55 % (5 mg) 77 % (15 mg)
Azathioprine, % (n) 28 % (n = 29) 31 % (n = 26) 13 % (n = 3)
Mycophenolate mofetil, % (n) 8 % (n = 8) 10 % (n = 8) 0
Rituximab, % (n) 19 % (n = 20) 19 % (n = 17) 17 % (n = 3)
Methotrexate, % (n) 14 % (n = 15) 14 % (n = 11) 17 % (n = 4)
Cyclophosphamide, % (n) 11 % (n = 11) 7 % (n = 6) 27 % (n = 6)
BVAS Birmingham Vasculitis Activity Score version 3, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, EGPA eosinophilic granulomatosis
with polyangiitis, MPO myeloperoxidase, ANCA anti-neutrophil cytoplasmic antibodies, PR3 proteinase 3, CRP C-reactive protein. aReference range 3.5–8.8 109/L.
bThere were 14 patients who did not receive any treatment
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As disease controls, patients (n = 26) with systemic
lupus erythematosus (SLE) were recruited to the study,
when attending their scheduled visit at the Department of
Rheumatology, Skåne University Hospital, Lund, Sweden.
All patients fulfilled at least four American College of
Rheumatology classification criteria for SLE [23]. Disease
activity was assessed using the Systemic Lupus Erythema-
tosus Disease Activity Index 2000 (SLEDAI-2 K) [24], and
organ damage was evaluated according to the Systemic
Lupus International Collaborative Clinics/American Col-
lege of Rheumatology damage index (SLICC/ACR-DI)
[25]. Blood donors (Blood center in Lund) and healthy
volunteers were recruited as controls (n = 112). Demo-
graphic data on age and gender were available for 102 of
the 112 controls, giving a median age of 49 years (range
19–74) and female to male ratio of 1.1 to 1.0. Patients with
AAV and controls were analyzed in parallel between 2011
and 2014. Patients with SLE were analyzed in parallel with
healthy controls and Patients with AAV during 2014.
The Regional Ethics Board in Lund, Sweden (LU) ap-
proved the study and informed consent was obtained
from all participants.
Phagocytosis and oxidative burst
Peripheral blood from patients and controls was collected
in vacutainer tubes containing sodium heparin (Becton
Dickinson, BD, New York, NY, USA). All samples were
analyzed within 24 h. The samples were stored at room
temperature and protected from light until analyzed.
Phagocytosis was investigated using the in vitro diagnostic
(IVD)-labeled PhagoTest assay (Glycotope Biotechnology,
GmBH, Germany), according to the manufacturer’s
protocol. This flow-cytometry-based method measures
the percentage of PMN and monocytes having ingested
fluorescein-labeled opsonized Escherichia coli (E. coli),
and mean fluorescence intensity (MFI) corresponds to
the number of ingested bacteria per cell. Production of
ROS in peripheral blood PMN and monocytes was
investigated using the IVD-labeled PhagoBurst assay,
(Glycotope Biotechnology, GmBH, Germany), according
to the manufacturer’s protocol, after ex vivo activation
with phorbol-12-myristate-13-acetate (PMA) or opsonized
E. coli. At least 15,000 PMN were collected based on for-
ward and side scatter properties. No patient had ROS
deficiency.
Phagocyte phenotypes
Peripheral blood from patients and controls was col-
lected in vacutainer tubes containing sodium heparin
(Becton Dickinson, BD, New York, USA). All sample
were analyzed within 24 h. The samples were stored at
room temperature and protected from light until analyzed.
The expression of selected surface markers on phagocytes
was analyzed using flow cytometry. Briefly, peripheral
blood was lysed, using 0.84 % ammonium chloride. The
remaining leukocytes were stained for surface expression
of CD10, CD16, CD62L (BD Bioscience, San Jose, CA,
USA), C5aR (CD88), CD11c (Biolegend, San Diego, CA,
USA) and CD177 (AbD Serotec, Raleigh, NC, USA) and
finally analyzed using a FACSCanto II and the DIVA soft-
ware (Becton Dickinson, Franklin Lakes, NJ, USA). Gating
strategies are shown in Additional file 1: Figure S1.
Statistical analysis
Correlation was assessed by Spearman’s test. The Mann-
Whitney U test was used for two-group comparisons,
and the Kruskal-Wallis and Dunn multiple comparisons
test was for three or more groups. All p values were
considered significant at p < 0.05. Prism for MacOS
version 5.0a was used for statistic calculations.
Results
Patient characteristics
The clinical and demographic characteristics of the
patients with AAV (n = 104) at the time of sampling
are reported in Table 1. The majority of the patients
were diagnosed with GPA (70 %), whereas patients
with MPA and EGPA represented 22 % and 8 % of
the cohort, respectively. Most patients were in remis-
sion and a little over 20 % of the patients had some
kind of disease activity according to the BVAS3, with
a median score of 4 (range 1–16). The median age of
the patients with SLE was 62 years (range 25–85) and
the female-to-male ratio was 3.5 to 1.0. Most SLE pa-
tients were in remission or had low disease activity
with a mean SLEDAI-2 K of 2 (range 0–6). The dis-
ease severity, defined as organ damage, was evaluated
using SLICC with a median score of 2 (range 0–6).
Of the SLE patients, 60 % were treated with prednis-
one (the mean dose in treated patients was 5 mg/day,
range 2.5–20.0 mg/day); 64 % were treated with hydroxy-
chloroquine and 54 % were treated with other immune
modulating drugs (methotrexate, mycophenolate mofetil
or azathioprine).
Signs of increased mobilization of PMN from bone
marrow in patients with AAV
The frequency of phagocytes and lymphocytes was evalu-
ated in peripheral blood from patients with AAV (n = 104)
and healthy controls (n = 112). Patients had an increased
percentage of PMN and a decreased number of lympho-
cytes compared with controls (p < 0.0001). There was no
difference in the number of monocytes (Table 2).
Elevated numbers of CD10-CD16low PMN in periph-
eral blood are thought to reflect increased mobilization
of neutrophils from the bone marrow [11, 12]. Patients
with AAV had a greater percentage of CD10-CD16low
PMN (p = 0,0079) (Table 2), suggesting elevated bone
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marrow release. There was no difference in the per-
centage of mature segment nucleated (CD10+CD16+)
neutrophils.
In neutrophils, surface translocation of proteinase 3
(PR3), one of the main ANCA targets, appears to occur
in association with CD177 [26–28]. In AAV-PMN there
were increased levels of CD177 on neutrophils (p = 0.0061)
(Table 2), which could indicate increased delivery of PR3 to
the cell surface of neutrophils. No CD177 was observed on
monocytes (data not shown).
To characterize the activation status of phagocytes in
peripheral blood, the expression of CD88 (C5aR), CD11c,
and CD62L were investigated. Mature segment nucleated
neutrophils (CD10+CD16+) from patients with AAV had
similar surface expression of these molecules as controls
(Table 2). Less surface expression of CD11c was observed
on the CD10+CD16dim PMN and monocytes from patients
with AAV. AAV monocytes also had increased expression
of CD62L (Table 2). Thus, phagocytes in patients with
AAV were not more activated than in healthy controls.
Decreased production of ROS in AAV phagocytes
ROS production is an important effector function of
phagocytes for defense against microbes, but also in the
regulation of the innate and adaptive immune system
[19, 29]. Production of ROS in phagocytes is generated
by the NADPH oxidase that resides in the plasma mem-
brane (5 %) and in granule membranes (95 %) in neutro-
phils. To evaluate phagocyte function in AAV, we decided
to investigate intracellular ROS production. PMN and
monocytes in peripheral whole blood from patients with
AAV (n = 104) (Table 1), SLE (n = 26), and healthy con-
trols (n = 112), were stimulated with either the protein
kinase C activator, PMA, or with opsonized E. coli. AAV
phagocytes, both PMN and monocytes, showed decreased
capacity to produce ROS after activation with phorbol
12-myristate 13-acetate (PMA) (p < 0.0001) or E. coli
(p < 0.0001, Fig. 1a and b) compared with healthy controls.
PMN from patients with AAV had less ROS formation
compared with PMN from patients with SLE after E. coli
stimulation (p < 0.0001) (Fig. 1a), but no significant dif-
ference was observed after PMA activation.
The patients were divided based on disease characteris-
tics into EGPA, GPA, or MPA. PMN from patients with
MPA (n = 23) had decreased burst capacity compared to
GPA (n = 73; p < 0.05) and EGPA patients (n = 8; p < 0.05)
after PMA activation (Fig. 2), whereas no significant differ-
ences were observed after E. coli stimulation (data not
shown). The ROS producing capacity was not associated
with the presence of PR3-ANCA or MPO-ANCA (data
not shown).
Decreased ROS formation is associated with disease
activity
The severity of autoimmune diseases has previously
been associated with decreased ROS production [30–32].
Hence, to study if the disease activity of AAV was associ-
ated with changes in ROS production, the patients were
divided in two groups based on disease activity accord-
ing to the BVAS3 (Table 1). PMN from patients with
BVAS3 ≥ 1 had decreased ROS production, compared
with patients in remission, when activated with E. coli
(p = 0,0306) (Fig. 3a) and PMA (p = 0,0471). Most pa-
tients in the disease activity group were diagnosed as
having GPA (n = 17) (Table 1). There was no associ-
ation between disease activity and ROS production in
monocytes (data not shown).
Prednisone treatment is common in this patient group
and affects phagocyte function. In this study, 60 % of
the patients were on prednisone treatment, with a
mean dose of 7.5 mg (range 2–80 mg) (Table 1). To in-
vestigate the corticosteroid effect on ROS production,






Monocytes (% of leukocytes) 4.4 ± 0.3 4.8 ± 0.24 n.s.
(109/L, reference range <1,1) 0.33 ± 0.02
Lymphocytes (% of leukocytes) 20 ± 1.2 31 ± 1.2 <0.0001
(109/L, reference range 1.1–4.8) 0.74 ± 0.05
PMN (% of leukocytes) 39 ± 1.3 28 ± 1.1 <0.0001
(109/L, reference range 1.7–8.0) 5.9 ± 0.3
CD16+CD10+ (% of PMN) 84 ± 1.1 82 ± 1.2 n.s.
CD16dimCD10- (% of PMN) 8.9 ± 0.8 6.8 ± 0.6 0.0109
CD177+ (% of PMN) 55 ± 2.4 47 ± 1.9 0.0075
CD10+CD16+ PMN
CD88+ (geoMFI) 442 ± 14 409 ± 15 n.s
CD62L+ (geoMFI) 1,277 ± 37 1,269 ± 41 n.s.
CD11c+(geoMFI) 558 ± 14 596 ± 16 n.s
CD10+CD16dim PMN
CD88+ (geoMFI) 391 ± 8.2 381 ± 7.6 n.s
CD62L+ (geoMFI) 450 ± 23 457 ± 22 n.s
CD11c+(geoMFI) 354 ± 7.2 428 ± 10 <0.0001
Monocytes
CD88+ (geoMFI) 162 ± 2.5 165 ± 2.5 n.s
CD62L+ (geoMFI) 770 ± 29 651 ± 37 <0.0001
CD11c+(geoMFI) 1,645 ± 63 2,079 ± 78 <0.0001
The frequencies of monocytes, lymphocytes, polymorphonuclear leukocytes
(PMN), CD10+CD16+ (mainly segment nucleated neutrophils) and CD10-
CD16dim (suggested as a marker for newly released neutrophils) were
investigated in healthy controls (n = 109) and patients (n = 105) using flow
cytometry. In addition, the level of surface expression of CD88 (C5aR), CD62L
and CD11c was studied on CD10+ CD16+ PMN, CD10 + CD16dim PMN and
monocyte populations, as a measurement of activation and reported as
geometric mean fluorescence intensity (geoMFI). The two-sided Mann-Whitney
test was used to calculate the level of significance. Values are reported as
mean ± SEM. AAV anti-neutrophil cytoplasmic antibodies associated vasculitides,
n.s. not significant
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the patients with disease activity (BVAS3 ≥ 1) or in re-
mission (BVAS3 = 0) were divided based on prednisone
treatment or not (Fig. 3b). Patients in remission with-
out prednisone had a higher burst capacity compared
with patients on prednisone treatment after E. coli
stimulation (p < 0.01). However, patients in remission
who were not receiving prednisone treatment still had
a decreased burst compared to healthy controls (p < 0.05).
In relation to corticosteroid treatment, there was no
difference in burst capacity in patients with BVAS ≥1.
Similar results were seen after PMA activation. One
patient in the group with disease activity was newly
diagnosed and not on any treatment at the time of
sampling. PMN from this patient had decreased burst
activity (geometric mean fluorescence intensity of 875 and
1053 after E. coli or PMA activation, respectively). In line
with the PMN, the monocytes from this patient also pro-
duced decreased amounts of ROS (171 and 218 after E.
coli or PMA activation, respectively (Fig. 3b).
Decreased phagocytosis in patients with AAV
Another important function of phagocytes is the phago-
cytosis of antibody-coated microbes and foreign material,
which often precedes the intracellular ROS production.
The capacity to phagocytose opsonized E. coli was investi-
gated in PMN and monocytes from patients with AAV
(n = 83) or SLE (n = 26) and controls (n = 54). Both
AAV PMN and monocytes had decreased phagocytosis
capacity, defined as the amount of phagocytosed E. coli
per cell compared with patients with SLE and healthy
controls (p < 0.0001) (Fig. 4a). The AAV PMN also had
a decreased percentage of phagocytosing cells (p < 0.0001)
(Fig. 4b). There was no association with disease activity,
corticosteroids or ANCA specificity (data not shown).
Discussion
PMN and monocytes from patients with AAV were char-
acterized with respect to bone marrow release, activation
and function. This study shows that patients with AAV
have increased mobilisation of neutrophils from the bone
marrow, impaired phagocyte functions, such as ROS pro-




Fig. 1 Phagocytes from patients with anti-neutrophil cytoplasmic
antibodies associated vasculitides (AAV) produced fewer reactive
oxygen species (ROS) than phagocytes from healthy blood donors.
The capacities of polymorphonuclear leukocytes (PMN) (a) or
monocytes (b) from healthy controls (HC) (n = 112), patients with
AAV (n = 104), and patients with systemic lupus erythematosus (SLE)
(n = 26) (only PMN) to produce ROS upon activation with phorbol
12-myristate 13-acetate (PMA) or opsonized E. coli were investigated
using flow cytometry. The amount of ROS produced is shown as
geometric mean fluorescence intensity (geoMFI). The two-sided
Mann-Whitney test was used to calculate the level of significance.
Horizontal lines represent the median value of each dataset
Fig. 2 Patients with microscopic polyangiitis (MPA) had lower
reactive oxygen species (ROS) formation compared with patients
with granulomatosis with polyangiitis (GPA) or eosinophilic
granulomatosis with polyangiitis (EGPA). ROS production was
measured by flow cytometry after ex vivo activation of peripheral
blood PMN with phorbol 12-myristate 13-acetate. Patients with anti-
neutrophil cytoplasmic antibodies associated vasculitides were divided
based on disease characteristics into EGPA, GPA or MPA. The amount
of ROS produced is shown as geometric mean fluorescence intensity
(geoMFI). The Kruskal-Wallis test with Dunn’s multiple comparison test
was used to calculate the level of significance. Line represents the
median value of each dataset
Johansson et al. Arthritis Research & Therapy  (2016) 18:92 Page 5 of 9
In line with earlier observations, we found that patients
with AAV had a decreased percentage of lymphocytes and
an increase of PMN. Low levels of lymphocytes are com-
mon on diagnosis of AAV and during flares [33] and
might also be an effect of immune suppressive treatment
[34, 35]. The increased percentage of PMN in patients
with AAV could be explained by increased survival in the
periphery in combination with elevated bone marrow
release. We have shown previously that AAV neutrophils
have a lower rate of apoptosis and longer in vitro survival
compared with healthy controls and patients with SLE
[36]. Furthermore, patients with AAV appeared to have an
increased release of neutrophils from the bone marrow,
measured as elevated numbers of CD16dimCD10- neutro-
phils in peripheral blood. Increased levels of CD177 were
observed on PMN, but there were no other obvious signs
of activation. The elevated expression of CD177 on PMN
is in concordance with prior findings [26, 27].
Our data support that patients with AAV have a de-
creased capacity to produce ROS in vivo. The association
with disease activity further strengthened our finding. Low
ROS production has been associated with disease severity
in other autoimmune conditions, including Behcet’s dis-
ease [30], Guillian-Barre syndrome [31], multiple sclerosis
[32] and SLE [37], and might be a common denominator
in maintaining chronic inflammation. Moreover, recent
findings in an ANCA-induced glomerulonephritis model
using mice deficient in either of the NADPH oxidase
subunits, gp91phox or p47phox [38], suggested that ROS
limit ANCA-induced inflammation by downregulating
a
b
Fig. 3 Disease activity in patients with anti-neutrophil cytoplasmic
antibodies associated vasculitides (AAV) is associated with decreased
production of reactive oxygen species (ROS). ROS production was
measured by flow cytometry after ex vivo activation of peripheral
blood polymorphonuclear leukocytes (PMN) with phorbol 12-myristate
13-acetate (PMA) or opsonized E. coli in a patients with AAV in
remission (Birmingham Vasculitis Activity Score version 3 (BVAS) = 0) or
with some kind of disease activity (BVAS ≥1). b Patients are additionally
divided based on prednisone treatment or not. The amount of ROS
produced is shown as geometric mean fluorescence intensity (geoMFI).
The two-sided Mann-Whitney test was used to calculate the level of
significance between two groups and the Kruskal-Wallis test with
Dunn’s multiple comparison test was used to calculate the level of
significance between more than two groups. Line represents the
median value of each dataset. HC healthy controls
a
b
Fig. 4 Decreased phagocytosis in anti-neutrophil cytoplasmic
antibodies associated vasculitides (AAV). To evaluate further the
function of phagocytes in AAV, the capacity to phagocytose opsonized
E. coli was investigated in polymorphonuclear leukocytes (PMN) and
monocytes from patients with AAV (n = 84), patients with systemic
lupus erythematosus (n = 26), and healthy controls (HC) (n = 54).
a Amount of phagocytosed E. coli bacteria shown as geometric
mean fluorescence intensity (geoMFI). b Percentage of phagocytos-
ing cells. Differences between healthy controls, patients with SLE,
and patients with AAV were calculated using the Kruskal-Wallis test
with Dunn’s multiple comparison test, and the following p values
were obtained for all three groups: geoMFI of PMN, p < 0.0001;
geoMFI of monocytes, p < 0.0001 and % phagocytosing cells of
PMN, p < 0.0001; and % phagocytosing cells of monocytes, p = 0.4091.
P values presented in the figure are for comparison between two groups
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caspase 1 and hence keep the inflammasome in check.
This finding supports an important role of ROS in regulat-
ing vasculitis.
In patients with AAV, monocytes and PMN had de-
creased capacity to phagocytose compared to patients
with SLE. This effect could not be explained by differ-
ences in age or treatment between the patient cohorts.
Furthermore, patients with AAV tended towards more
compromised burst formation than patients with SLE.
Using, the same methods as in this report, Taylor et al.
saw a similar scenario in which patients with subacute
liver failure had decreased phagocytosis, whereas pa-
tients with acute liver failure or sepsis did not differ
from healthy controls [39]. Future studies are needed to
explain these differences.
Patients with MPA had decreased ROS production
compared to patients with GPA or EGPA, suggesting
more impaired phagocyte function in these patients. The
patients with MPA were slightly older than those with
GPA (median age 72 and 66 years, respectively) and an
age-dependent difference in the effect on ROS produc-
tion in these two groups could not be excluded; however,
no correlation between age and ROS production was
seen (data not shown). Future studies designed to inves-
tigate this difference would be of interest.
Observations from a genome-wide association study
have suggested that PR3-AAV and MPO-AAV are distinct
autoimmune syndromes with different genetic phenotypes
[40]. Interestingly, by dividing patients based on ANCA
specificity, rather than clinical diagnosis, no differences in
ROS production were observed. This indicates that de-
creased ROS formation might be associated with chronic
inflammatory processes giving rise to the clinical picture,
rather than specifically linked to ANCA pathogenesis.
Corticosteroids have been reported to affect ROS pro-
duction in PMN in a cumulative dose-dependent way
[41], and it is presently unclear whether this effect is due
to increased disease severity. In a previous report on
PMN function in SLE there was no correlation between
corticosteroid dose and the amount of intracellular ROS
produced. However, the patients were receiving relatively
low doses of corticosteroids (mean = 5 mg oral prednis-
one/day in treated patients) [37]. In the present study
we observed that patients in remission who were receiv-
ing ongoing prednisone treatment had decreased burst
compared with patients not on prednisone, suggesting
that in this case a minor effect of prednisone on ROS
formation could not be excluded. On the other hand,
patients with a tendency to recurrent flares or having
low grade activity (not captured by the BVAS) frequently
remain on prednisone treatment during remissions, hence
patients in remission who are on prednisone treatment
might have another kind of inflammatory phenotype that
is reflected by decreased ROS formation.
In general, prednisone treatment could not explain the
decreased ROS production in patients with AAV, as the
patients in remission who were not being treated with
prednisone had a decreased burst compared with con-
trols. In addition, a newly diagnosed patient who was
not on any treatment at the time of sampling had low
burst activity.
We have previously reported that PR3-ANCA induced
increased intracellular but not extracellular ROS produc-
tion in PMN from patients with AAV [42]. The activa-
tion and control of the NADPH oxidase in neutrophils
(NOX2) is incompletely understood. Different agonists
encountered by the neutrophil engage different combi-
nations of kinases, and thereby affect the degree of activ-
ity of the NADPH complex, and in the end the amount
of ROS produced [43]. Hence, the different results in
PR3-ANCA-induced ROS on one hand and E. coli or
PMA on the other hand, might be due to the different
routes of NADPH activation: PR3-ANCA activates by
binding to membrane-bound PR3; opsonized E. Coli by
receptor mediated phagocytosis; and PMA by activation
of protein kinase C.
Conclusions
The phagocytes in AAV were found to have decreased
functions such as lower ROS formation and phagocytosis,
compared to healthy controls. The decreased ROS pro-
duction is consistent with findings in other autoimmune
diseases and might be a risk factor in autoimmunity and a
common denominator maintaining chronic inflammation.
Although increased expression of CD177 was observed on
PMN, no other clear signs of activation were seen. The
increased percentage of PMN in peripheral blood might
be due to a combination of increased bone marrow release
and prolonged survival. Future studies will illuminate
the role of ROS formation and PMN in AAV and
autoimmunity.
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